Drug Profile


Alternative Names: BCX-4208; R3421; RO5092888; Ulodesine succinate

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Albert Einstein College of Medicine; Industrial Research Limited
  • Developer BioCryst Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antipsoriatics; Pyrimidinones; Pyrrolidines
  • Mechanism of Action Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gout
  • Discontinued Plaque psoriasis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Jun 2015 Ulodesine is still in phase II development for Gout in USA
  • 30 Jun 2015 Ulodesine is still available for licensing as of 30 Jun 2015. http://www.biocryst.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top